$10.32
1.13% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Cullinan Oncology Inc Stock price

$10.20
-1.58 13.41% 1M
-7.35 41.88% 6M
-1.98 16.26% YTD
-7.80 43.33% 1Y
-3.00 22.73% 3Y
-10.80 51.43% 5Y
-10.80 51.43% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.14 1.39%
ISIN
US2300311063
Symbol
CGEM
Sector
Industry

Key metrics

Market capitalization $593.92m
Enterprise Value $18.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.94
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-187.36m
Free Cash Flow (TTM) Free Cash Flow $-126.81m
Cash position $578.08m
EPS (TTM) EPS $-2.88
P/E forward negative
Short interest 19.47%
Show more

Is Cullinan Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Cullinan Oncology Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Cullinan Oncology Inc forecast:

Buy
100%

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.31 0.31
7% 7%
-
-0.31 -0.31
7% 7%
-
- Selling and Administrative Expenses 49 49
16% 16%
-
- Research and Development Expense 137 137
2% 2%
-
-187 -187
5% 5%
-
- Depreciation and Amortization 0.31 0.31
7% 7%
-
EBIT (Operating Income) EBIT -187 -187
5% 5%
-
Net Profit -144 -144
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cullinan Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cullinan Oncology Inc Stock News

Positive
Seeking Alpha
26 days ago
Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalertinib targets a tiny niche in the large NSCLC market. Management expects to report its Phase 2b results by mid-2025. Similarly, CLN-978 is a first-in-class T-cell engager targeting SLE and RA. It can...
Positive
Seeking Alpha
28 days ago
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon 20 insertion mutation-positive NSCLC, with a 40% objective response rate in early phase trials. CGEM has a strong financial position with cash reserves projected to fund operations into 2028, reduci...
More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Nadim Ahmed
Employees 85
Founded 2016
Website cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today